目的 探討葛根枳椇子梔子提取物（PHGE）解酒護肝作用。方法 SPF級Wistar雄性大鼠120只，隨機分為對照組、模型組和PHGE低、中、高劑量（0.2、0.5、1.2 g/kg）組，每組24只。除對照組外，其他組別通過喂飼Regular型Lieber-DeCarli酒精液體模型飼料造模，造模過程中，PHGE各組動物ig不同劑量的PHGE。每周測定動物體質(zhì)量1次，每天測定攝食量1次；給藥4周和8周每組分別取半數(shù)動物禁食過夜，采血測定血清生化指標(biāo)；解剖取肝臟稱質(zhì)量并計算臟體系數(shù)；取部分肝臟冰凍切片進行油紅“O”染色，觀察肝臟脂肪肝情況；測定肝臟總脂肪含量，測定肝臟組織超氧化物歧化酶（SOD）、丙二醛（MDA）、總谷胱甘肽（GSH）、乙醇脫氫酶（ADH）和乙醛脫氫酶（ALDH）。結(jié)果 4周和8周造模，大鼠體質(zhì)量均增長減緩（P<0.05、0.01），第8周PHGE高劑量組動物體質(zhì)量顯著低于模型組（P<0.05）；攝食量未見明顯差異。造模4周，模型組血清丙氨酸轉(zhuǎn)氨酶（ALT）、天冬氨酸轉(zhuǎn)氨酶（AST）、總膽固醇（TCHO）、高密度脂蛋白膽固醇（HDL）、低密度脂蛋白膽固醇（LDL）、血糖（GLU）顯著高于對照組（P<0.05、0.01）；與模型組比較，PHGE低、中、高劑量組AST、GLU，中、高劑量組ALT、TCHO、HDL，中劑量組LDL均顯著下降（P<0.05、0.01），并呈明顯的劑量相關(guān)性，造模8周與造模4周結(jié)果一致。造模給藥8周，模型組GSH顯著高于對照組（P<0.01），PHGE高劑量組GSH顯著高于模型組（P<0.01），高劑量組ADH顯著高于模型組（P<0.05）；與對照組比較，造模給藥4、8周，模型動物肝臟脂肪量顯著升高（P<0.05、0.01），給藥8周，PHGE高劑量組肝臟脂肪量顯著低于模型組（P<0.05）。模型組肝臟質(zhì)量與對照組比較未見顯著性差異，而肝臟系數(shù)顯著增加（P<0.01），應(yīng)為動物體質(zhì)量較小引起，PHGE各劑量組肝臟系數(shù)與同期模型組比較未見顯著性差異。肝臟脂肪染色后，造模動物主要表現(xiàn)為彌漫性肝細胞內(nèi)、中央靜脈周邊肝細胞內(nèi)紅染脂滴，PHGE中、高劑量組評分低于模型組。結(jié)論 PHGE發(fā)揮明顯預(yù)防和/或改善酒精性脂肪肝的作用，改善肝功能，降低血糖和膽固醇。

Objective To study the efficacy of Puerariae Lobatae-Hovenia acerba-Gardeniae Fructus extractive (PHGE) for antialcohol and hepato-protection. Methods Rat model of alcoholic fatty liver was induced by feeding with 5% ethanol-containing Lieber-DeCarli liquid diet for 4 and 8 weeks. 120 SPF Wistar male rats were assigned into 5 groups, include vehicle control, model control and treatment groups which were 0.2, 0.5, 1.2 g/kg Gegen-Zhijuzi-Zhizi extract. Food consumption was detected daily. And body weight was detected weekly. Animals were sacrificed after overnight fasting at 4 and 8 weeks of study. Blood samples were collected for biochemical analysis. Livers were weighed, and prepared for histopathological examination with oil red O stain. The content of liver ADH, ALDH, GSH, SOD and MDA in rats were also determined. Result After 4 and 8 weeks, the body weight gained of rats slowed down (P<0.05, 0.01). At 8 weeks, the body weight of rats in the high dose PHGE group was significantly lower than that of the model group (P<0.05), and there was no significant difference in food intake. After 4 weeks, the levels of ALT, AST, TCHO, HDL, LDL and GLU in the model group were significantly higher than those in the control group (P<0.05, 0.01). Compared with the model group, AST and Glu in PHGE low, middle and high dose group, ALT, TCHO, HDL in middle and high dose group, and LDL of middle dose group were significantly decreased, and showed significant dose dependence. The results of 8 weeks and 4 weeks were consistent. After 8 weeks, GSH in model group was significantly higher than that in control group (P<0.01), GSH in high dose PHGE group was significantly higher than that in model group (P<0.01), and ADH in high dose PHGE group was significantly higher than that in model group (P<0.05). There was no significant difference in liver weight between the model group and the control group, but the liver relative weight increased significantly (P<0.01), which should be caused by the small lower lever of animal weight. There was no significant difference in liver relative weight between the PHGE dose groups and the model group at the same time. After liver fat staining, diffuse hepatocytes and peripheral hepatocytes of central vein were the main manifestations of model animals. The score of middle and high dose PHGE group was lower than that of model group. Conclusions PHGE plays a significant role in preventing and/or improving alcoholic fatty liver, improving liver function, reducing blood sugar and cholesterol.